Vivesto AB
Suletud
0
Ülevaade
Aktsiahinna muutus
24h
Min
Max
Sissetulek | -1.9M -9.1M |
|---|---|
Aktsiakasum | -0.015 |
Töötajad | 4 |
EBITDA | -1.8M -8.9M |
Järgmine tulemuste avaldamine | 7. mai 2026 |
|---|
Turukapital | 38M 90M |
|---|---|
Eelmine avamishind | 0 |
Eelmine sulgemishind | 0 |
Vivesto AB Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Vivesto AB Prognoos
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Vivesto AB
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.
